Navigation Links
Commencement of GMP Production Project for Lead Anti-Cancer Product PAT-LM1
Date:6/2/2011

bust and productive. We expect that this platform will be very competitive in the field of antibody production."

Patrys CEO Dan Devine added that securing the manufacturing for PAT-LM1 was an important milestone toward evaluating PAT-LM1 in a first-in-human clinical trial in 2012.

The PAT-LM1 project has recently commenced at Laureate.

For further information, please contact:Patrys Limited:

Patrys IR:

Patrys Media:Daniel Devine

Rebecca Wilson

Tom DonovanChief Executive Officer

Buchan Consulting

Buchan ConsultingP: +61 3 9670 3273  

P: 0417 382 391

P: +61 3 9866 4722info@patrys.com

rwilson@bcg.com.au

tdonovan@bcg.com.auAbout Patrys Limited:Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases.  Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities.  More information can be found at www.patrys.com.

About PAT-LM1:PAT-LM1 is a natural human antibody that has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies.  This lead product binds to a proprietary disease target that is expressed on the surface of cancer cells, but not on the surface of the healthy tissues screened.  With over 200 individual patient tumours screened, covering several different cancers, PAT-LM1 binds to nearly 98% of those tumours regardless of cancer type, age, gender or disease stage.  Patrys has filed patent applications to cover the PAT-LM1 molecule and its disease target.  

About PAT-SM6: The natural human antibody PAT-SM6 has been shown to have potent anti
'/>"/>

SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
2. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
3. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
4. Watson Announces Commencement of Secondary Offering by Selling Stockholder
5. Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer
6. Cogdell Spencer Announces Commencement of Common Stock Offering
7. U.S. Surgeon General Dr. Regina M. Benjamin to Deliver Commencement Address at Albany College of Pharmacy and Health Sciences
8. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from Chinas SFDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... results of a Phase 2b trial for Empatic(TM) on Wednesday, ... will be followed by a live webcast and conference call ... the call and webcast to discuss the results of this ...
... Pharmaceutical Major, Lupin Ltd. announced today the acquisition of ... mg). Lupin acquired the product from Oscient Pharmaceuticals on ... Court. Antara recorded net sales of US $ 70 ... $ 38.61 million for the product and related assets inclusive ...
Cached Medicine Technology:Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:7/11/2014)... 2014 AngelWeddingDress is now providing worldwide ... summer collections ”. When it comes to buying summer ... AngelWeddingDress with the unlimited stock of beautiful wedding gowns. ... its wonderful summer wedding gowns. , The company’s ... to keep pace with the newest fashion trends. The ...
(Date:7/11/2014)... American Farmer is proud to announce ... 15, 2014, at 8:30 am ET. , In this ... which are designed and formulated for use on a ... these products help the crop realize its maximum genetic ... grown. , The show also features UniSouth Genetics, a ...
(Date:7/11/2014)... 11, 2014 Alliance Labs announced that ... Innovations with Ed Begley Jr, airing later this year ... , In this episode, Innovations will explore DocuSol® Kids, ... sodium in polyethylene glycol base designed to give adolescents ... formulation functions as a hyperosmotic laxative by drawing water ...
(Date:7/11/2014)... 11, 2014 College athletes experiencing in-season ... of injury, but developed recurrent instability in 63% of ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... in providing the most optimal treatment plans for injured ... anterior shoulder instability event, and found that 33 (73%) ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... workers in the United States has risen, so has ... ,According to Vanderbilt infectious disease experts Timothy R. ... be provided to health care workers with latent TB ... particularly if they meet certain high-risk criteria. ...
... researchers has discovered a new protein called as P2 ... epithelial cells// that regulates the allergic airway inflammation. ... study that the adipocyte/macrophage fatty acid–binding protein aP2, which ... of fatty acids and has been previously linked to ...
... the open access journal Substance Abuse Treatment, Prevention and policy ... training treats the alcohol dependent patients better for a long ... by trained GPs who abstain from drinking alcohol is more ... basic training alone at the medical school. Also the ...
... duvets used by most Britons are packed with dust mites, fungus ... duvets it was found to contain up to 20,000 live house ... analysis of an 11-year unwashed duvet revealed over an ounce and ... faeces. ,In addition it was found that more than ...
... new research, the risk of heart diseases is reduced on ... the University of Bristol in the UK and colleagues conducted ... between 44 to 65, and found a direct association between ... of the thickness of blood vessel walls that is used ...
... Danish researchers, in their new studies have concluded that ... suffer from a serious heart condition when compared to ... ,Research by Kirsten Melgaard Nielsen, Ph.D., and colleagues, of ... after obtaining data on 138,000 adults between the ages ...
Cached Medicine News:Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Dust mites use Duvets as their Haven 2Health News:Long Legs Reduces The Chances Of Heart Disease 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: